MCET (MultiCell Technologies) Cyclically Adjusted PB Ratio: (As of Sep. 06, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is MultiCell Technologies Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


MultiCell Technologies  (OTCPK:MCET) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


MultiCell Technologies Cyclically Adjusted PB Ratio Related Terms


MultiCell Technologies Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for MultiCell Technologies's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MultiCell Technologies Cyclically Adjusted PB Ratio Chart

MultiCell Technologies Annual Data
Trend Nov05 Nov06 Nov07 Nov08 Nov09 Nov10 Nov11 Nov12 Nov13 Nov14
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

MultiCell Technologies Quarterly Data
Nov10 Feb11 May11 Aug11 Nov11 Feb12 May12 Aug12 Nov12 Feb13 May13 Aug13 Nov13 Feb14 May14 Aug14 Nov14 Feb15 May15 Aug15
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

MCET vs ERGO, OPLI, GLAG: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, MultiCell Technologies's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MultiCell Technologies Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MultiCell Technologies's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where MultiCell Technologies's Cyclically Adjusted PB Ratio falls into.



MultiCell Technologies Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

MultiCell Technologies's Cyclically Adjusted Book per Share for the quarter that ended in Aug. 2015 is calculated as:

For example, MultiCell Technologies's adjusted Book Value per Share data for the three months ended in Aug. 2015 was:

Adj_Book=Book Value per Share/CPI of Aug. 2015 (Change)*Current CPI (Aug. 2015)
=-0/238.3160*238.3160
=0.000

Current CPI (Aug. 2015) = 238.3160.

MultiCell Technologies Quarterly Data

Book Value per Share CPI Adj_Book
200511 0.082 197.600 0.099
200602 0.065 198.700 0.078
200605 0.034 202.500 0.040
200608 0.004 203.900 0.005
200611 -0.037 201.500 -0.044
200702 -0.049 203.499 -0.057
200705 -0.046 207.949 -0.053
200708 -0.051 207.917 -0.058
200711 -0.048 210.177 -0.054
200802 -0.047 211.693 -0.053
200805 -0.041 216.632 -0.045
200808 -0.047 219.086 -0.051
200811 -0.064 212.425 -0.072
200902 -0.034 212.193 -0.038
200905 -0.027 213.856 -0.030
200908 -0.017 215.834 -0.019
200911 -0.011 216.330 -0.012
201002 -0.011 216.741 -0.012
201005 -0.009 218.178 -0.010
201008 -0.007 218.312 -0.008
201011 -0.007 218.803 -0.008
201102 -0.005 221.309 -0.005
201105 -0.004 225.964 -0.004
201108 -0.004 226.545 -0.004
201111 -0.003 226.230 -0.003
201202 -0.003 227.663 -0.003
201205 -0.003 229.815 -0.003
201208 -0.002 230.379 -0.002
201211 -0.001 230.221 -0.001
201302 -0.001 232.166 -0.001
201305 0.000 232.945 0.000
201308 0.000 233.877 0.000
201311 0.000 233.069 0.000
201402 0.000 234.781 0.000
201405 0.000 237.900 0.000
201408 0.000 237.852 0.000
201411 0.000 236.151 0.000
201502 0.000 234.722 0.000
201505 0.000 237.805 0.000
201508 0.000 238.316 0.000

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


MultiCell Technologies Business Description

Address 4144 North Central Expressway, Suite 600, Dallas, TX, USA, 75204
MultiCell Technologies Inc is a biopharmaceutical company. It is engaged in developing novel therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease, cancer, and others. Its therapeutic development platform includes several patented techniques used to isolate, characterize, and differentiate stem cells from the human liver or control the immune response at transcriptional and translational levels through dsRNA-sensing molecules, such as Toll-like receptor, RIG-I-like receptor, and MDA-5 signaling. The company's medical device development platform is based on the design of a next-generation bioabsorbable stent, the Ideal BioStent, for interventional cardiology and peripheral vessel applications. All the operations are functioned within United States.